Related news and resources
Industry perspectives on implementation of Quality Overall Summary-Product Dossier (QOS-PD) and Quality Information Summary (QIS) for innovative medicinal products
In view of a growing complexity of product lifecycle management, industry puts forward perspectives to support the harmonization of regulatory requirements. These are intended to facilitate efficient regulatory review and approval to support timely implementation of changes and product improvements, leading to more resilient supply chains.
Read more
Renewed partnership to boost the skills needed to drive drug discovery and development in Africa
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and H3D Foundation have today announced a new three-year phase of their partnership, aiming to boost the skills and capacity needed to drive increased research and development of new medicines in Africa.
Read more
IFPMA welcomes announcement of first three regulatory agencies listed under WHO Listed Authorities Framework
On 2 November, IFPMA and its member associations in South Korea, Singapore and Switzerland have welcomed the appointment of the Korean Ministry of Food and Drug Safety (MFDS) of South Korea, the Health Sciences Authority (HSA) of Singapore, and Swissmedic of Switzerland as the first three Listed Authorities under the WHO Listed Authorities (WLA) framework.
Read more